AstraZeneca-Backed JV Sued By Genentech Over Avastin Biosimilar
Centus Biotherapeutics Refuses To Delay Launch Until Litigation Resolved
Executive Summary
With the US biosimilar Avastin market now more than a year old, another potential player, Centus Biotherapeutics, finds itself facing trial over its biosimilar candidate. The UK-based joint venture already boasts approval from the European Commission for its FKB238 product, Equidacent.